Document is current

Article History

Accepted: 11 February 2025

First Online: 17 April 2025

Declarations

:

: The authors confirm that there was no competing interests or conflicts with the content of this article to declare.

: No funding was received for conducting this study.

: Gregory D. Myer consults with commercial entities to support commercialization strategies and applications to the US Food and Drug Administration but has no direct financial interest in the commercialization of the products. Dr. Myer’s institution receives current and ongoing grant funding from National Institutes of Health/NIAMS Grants U01AR067997, R01 AR070474, R01AR055563, R01AR076153, R01 AR077248, R61AT012421, the Department of Defense W81XWH22C0062 and Arthritis Foundation OACTN. Dr. Myer has received industry-sponsored research funding to his institutions related to injury prevention, sport performance and has current ongoing funding from Arthrex, Inc. to evaluate ACL surgical treatment optimization strategies. Dr. Myer receives author royalties from Human Kinetics and Wolters Kluwer. Dr. Myer is an inventor of biofeedback technologies (patent no. US11350854B2, Augmented and Virtual Reality for Sport Performance and Injury Prevention Application, approval date 06/07/2022, Software Copyrighted) designed to enhance rehabilitation and prevent injuries that receives licensing royalties.

: All data and material reported in this systematic review are from peer-reviewed publications and have been included in this study as tables, figures and supplementary material. Any other data requirement can be directed to the corresponding author upon reasonable request.

: Not applicable.

: Not applicable.

: Not applicable.